Overview

Sunitinib malate

CAS

341031-54-7

Status

Development

Sunitinib maleate belongs to the group of tyrosine kinase receptor inhibitors. The active substance inhibits different cell proliferation-associated and especially with tumor growth-related receptors. It is used for the treatment of metastatic malignant gastrointestinal stromal tumors.

Description

Formula

C22H29FN4O3 • C4H4O4

Molecular weight

398.47 g/mol

Molecular size

small

Controlled Substance

no

Precursor

no

Indications

Antineoplastic drugs

Your Contact

Marius Hang

Marius Hang

International Division
Director API Export

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
  • Disclaimer

    The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

    No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.

Complementary Services

Share this page